共 85 条
[1]
Culyer T(2014)Where are the Limits of Cost-Effectiveness Analysis and Health Technology Assessment? J Med Assoc Thai 97 S1-S2
[2]
Dolan JG(2010)Multi-criteria clinical decision support: A primer on the use of multiple criteria decision making methods to promote evidence-based, patient-centered healthcare Patient 3 229-248
[3]
Picavet E(2014)Shining a light in the black box of orphan drug pricing Orphanet J Rare Dis 9 62-762
[4]
Morel T(2014)Are pricing and reimbursement decision-making criteria aligned with public preferences regarding allocation principles in the Polish healthcare sector? Expert Rev Pharmacoecon Outcomes Res 14 751-165
[5]
Cassiman D(2014)The paradox of public participation in the healthcare in Poland - what citizens want, and what they think Health Policy 118 159-449
[6]
Simoens S(2013)Assessment of the attitudes of the general public towards supplementary criteria to be used in P&R decision making process in Poland Int J Technol Assess Health Care 29 443-97
[7]
Kolasa K(2014)Orphan drug considerations in Health Technology Assessment in eight European countries. Rare Diseases and Orphan Drugs An Int J Public Health 1 83-1024
[8]
Kolasa K(2013)Orphan drugs, orphan diseases. The first decade of orphan drug legislation in the EU Eur J Clin Pharmacol 69 1009-1169
[9]
Dohnalik J(2013)A pilot study of multicriteria decision analysis for valuing orphan medicines Value Health 16 1163-496
[10]
Borek E(2011)Access to orphan drugs despite poor quality of clinical evidence Br J Clin Pharmacol 71 488-S6